Industry Overview: India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 percent of global demand for various vaccines, 40 percent of the generic market in the US, and 25 percent of all medications in the UK.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Over 80 percent of the antiretroviral drugs used globally to combat AIDS (Acquired Immuno Deficiency Syndrome) are supplied by Indian pharmaceutical firms. The pharmaceutical sector was valued at US$ 33 billion in 2017. The country’s pharmaceutical industry is expected to expand at a CAGR of 22.4 percent over 2015–20 to reach US$ 55 billion. India’s pharmaceutical exports stood at US$ 17.27 billion in 2017-18 and are expected to reach US$ 20 billion by 2020. Indian companies received 304 Abbreviated New Drug Application (ANDA) approvals from the US Food and Drug Administration (USFDA) in 2017. The country accounts for around 30 percent (by volume) and about 10 percent (value) in the US$ 70-80 billion US generics market. India’s biotechnology industry comprising bio-pharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics is expected to grow at an average growth rate of around 30 percent a year and reach US$ 100 billion by 2025. Biopharma, comprising vaccines, therapeutics, and diagnostics, is the largest sub-sector contributing nearly 62 percent of the total revenues at Rs 12,600 crore (US$ 1.89 billion).
Company profile: The Company is India’s largest biopharmaceutical biotechnology company. The Company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics and biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon’s biosimilar products are sold in bulk and formulations in several emerging markets. Biocon’s formulations for the Indian market straddle Metabolics, Oncology, Immunotherapy, Nephrology, and Specialty. Some of Biocon’s critical brands in India include INSUGEN (RH-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Everton (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb(Itolizumab) and KRABEVA (Bevacizumab), which are claimed to be considerably less expensive than other leading brands.
Shareholding Pattern: BSE Data
Financial and ratio : [table id=132 /]
Prospects: A biosimilar (also known as follow-on biologics or subsequent entry biologic) is a biologic medical product that is almost identical to an original product that a different company manufactures. The Company is making it, which is, in fact, a large market. The Company made significant investments and took time to develop biosimilars. This strategy is expected to pay off in the upcoming time and point. Syngene is one asset of the Company. With the growth in the pharma sector, the Company will also grow.
